1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Bristol-Myers Squibb CompanyUS flagNew York Stock Exchange
60.57
USD
+1.29
- -
123.73BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
9.97
9.58
9.93
11.63
12.63
13.82
15.33
18.83
21.54
21.67
21.75
23.83
23.69
24.13
Basic EPS, GAAP
1.56
1.21
0.94
2.67
0.61
3.01
2.02
-3.99
3.25
2.97
3.88
-4.41
3.47
4.55
Free Cash Flow per Basic Share
1.83
1.58
1.26
1.83
3.21
4.33
4.82
6.22
7.53
6.13
6.7
7.49
6.96
6.27
Dividend per Share
1.4
1.45
1.49
1.52
1.57
1.6
1.57
1.8
2.04
2.18
2.29
2.4
2.48
2.5
Book Value per Share
9.23
8.98
8.59
9.72
7.23
8.64
23.16
17.03
16.7
14.97
14.56
8.05
9.07
10.93
Tangible Book Value per Share
3.5
3.67
3.59
4.76
2.26
3.94
-15.65
-16.29
-12.69
-12.74
-9.51
-14.31
-11.12
-8.35
Basic Weighted Avg Shares
1,644
1,657
1,667
1,671
1,645
1,633
1,705
2,258
2,153
2,130
2,069
2,027
2,034
2,038
Sales/Revenue/Turnover
16,385
15,879
16,560
19,427
20,776
22,561
26,145
42,518
46,385
46,159
45,006
48,300
48,195
49,187
Operating Margin (%)
17.89
10.79
10.45
23.36
16.59
22.79
16.5
5.15
18.4
19.72
18.21
12.19
28.48
28.14
Depreciation Expense
763
467
376
382
789
637
1,746
10,380
10,686
10,276
9,760
9,600
4,011
3,176
Net Income, GAAP
2,563
2,004
1,565
4,457
1,007
4,920
3,439
-9,015
6,994
6,327
8,025
-8,948
7,054
9,282
Effective Tax Rate (%)
10.76
14.78
21.47
23.8
81
17.11
30.45
- -
13.39
17.74
4.74
- -
24.36
22.12
Profit Margin (%)
15.64
12.62
9.45
22.94
4.85
21.81
13.15
-21.2
15.08
13.71
17.83
-18.53
14.64
18.87
Working Capital
6,476
6,147
2,398
4,863
5,291
7,062
11,050
11,112
11,394
5,383
9,508
6,006
5,973
9,920
LT Debt
7,981
7,242
6,550
5,716
6,975
5,646
44,059
49,169
40,479
36,317
38,183
48,973
44,676
43,819
Total Equity
15,236
14,983
14,424
16,347
11,847
14,127
51,698
37,882
36,006
31,118
29,485
16,388
18,506
22,319
Return on Invested Capital (%)
11.69
6.26
6.1
15.51
3.06
20.59
4.92
- -
8.64
9.75
10.86
- -
15.61
15.9
Return on Capital (%)
12.21
9.28
7.48
20.53
5.02
24.44
6.42
- -
9.5
9.54
12.78
- -
12.73
15.67
Return on Common Equity (%)
17.81
13.36
10.75
29.28
7.21
38.18
10.48
-20.16
18.96
18.88
26.53
-39.1
40.53
46.7

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,463
2,506
1,234
LT Borrowings
42,850
42,152
42,093
LT Finance Leases
1,826
1,770
1,726
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,036
2,042
2,042
Market Capitalization
109,809
123,831
117,645

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
29,390
27,208
28,579
Cash, Cash Equivalents & STI
10,673
10,486
11,067
Accounts Receivable, Net
9,592
7,947
9,077
Inventories
2,690
2,756
2,737
Total Current Liabilities
23,417
19,158
18,659
Payables & Accruals
6,321
6,936
6,839
ST Debt
2,463
2,506
1,234
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.9%
-11.06%
12.92%
Free Cash Flow
24.39%
0.97%
-6.81%
Net Income, GAAP
-44.69%
-110.12%
-178.83%
Sales/Revenue/Turnover
12.46%
2.64%
-0.22%
Total Cash Common Dividend
8.2%
4.38%
3.74%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11,865
12,201
11,892
12,342
48,300
2025
11,201
12,269
12,222
12,503
48,195
2026
11,489
12,973
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-5.89
0.83
0.6
0.04
-4.41
2025
1.21
0.64
1.08
0.53
3.47
2026
1.31
1.62
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.6
0.6
0.6
0.6
2.4
2025
0.62
0.62
0.62
0.62
2.48
2026
0.63
0.63
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Christopher Boerner
Full Time Employees
32,500
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
Route 206 & Province Line Road Princeton NJ United States of America 08543
IPO Date
Jun 1, 1972
CIK
0000014272
Website
bms.com
Similar Companies
BioDelivery Sciences Intl, Inc. Wrrt (BDSIW)
Pfizer Inc. (PFE.TO)
Johnson & Johnson (JNJ.DE)
PharmGen Science, Inc. (004720.KS)
GSK plc (GSK)
Gilead Sciences, Inc. (GILD)
Business
Bristol-Myers Squibb Company (NYSE: BMY), a global biopharmaceutical company headquartered in Princeton, New Jersey with roots tracing to mergers of entities founded in 1858 and 1887, discovers, develops, manufactures, and commercializes innovative medicines for serious diseases including cancer, immunology, cardiovascular, hematology, and neuroscience disorders; its primary products include the anticoagulant Eliquis (apixaban), oncology therapies such as Opdivo (nivolumab), Yervoy, Krazati, and Revlimid (lenalidomide), cell therapies Abecma and Breyanzi, immunomodulators like Orencia and Pomalyst, legacy brands such as Abraxane, Camzyos for hypertrophic cardiomyopathy, Cobenfy in neuroscience, and others including Baraclude, IDHIFA, Inrebic, Nulojix, Opdivo Qvantig, Reblozyl, and Thalidomid; the company operates in more than 120 countries with a focus on oncology, hematology, immunology, cardiovascular, and fibrotic diseases targeting patients with high unmet needs. In recent developments, Bristol-Myers Squibb completes the acquisition of Orbital Therapeutics in 2025 to strengthen its cell therapy portfolio with RNA medicines reprogramming the immune system; it forms a joint venture with Bain Capital in July 2025 for innovative immunology therapies and enters a global strategic partnership with BioNTech in June 2025 to co-develop and co-commercialize next-generation bispecific antibody BNT327 for multiple solid tumors; earlier, the company acquires 2seventy bio in March 2025 for full control of Abecma amid competitive pressures, completes acquisitions of Karuna Therapeutics in March 2024 to bolster neuroscience, RayzeBio in February 2024 for actinium-based radiopharmaceuticals, and Mirati Therapeutics in January 2024 to diversify oncology, alongside a $380 million capacity agreement with Cellares in April 2024 for CAR T manufacturing.

Company News

Company News APIChatGPT

  • 247wallst.com

    These 4 Dividend Stocks Passed the 2020 Stress Test. Are They Buys in Now October?

  • zacks.com

    Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

  • 247wallst.com

    Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

  • fool.com

    Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

  • zacks.com

    BMY Reports Mixed Phase III Trial Results, Stock Down

  • businessinsider.com

    FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban

  • zacks.com

    Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today

  • proactiveinvestors.com

    Bristol Myers falls 3% despite positive cancer drug trial results

  • benzinga.com

    Why Is Contineum Therapeutics Stock Falling Monday?

  • zacks.com

    BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock?

  • gurufocus.com

    Bristol Myers Squibb (BMY) Gains on Positive Phase 3 Results for RYZ101 and Admilparant

  • businesswire.com

    Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETs

  • businesswire.com

    Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

  • fool.com

    Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

  • defenseworld.net

    20,370 Bristol Myers Squibb Company $BMY Shares Bought by Apella Capital LLC

  • fool.com

    Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

  • zacks.com

    Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

  • benzinga.com

    Bristol Myers Squibb's Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%

  • businesswire.com

    Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs.

  • seekingalpha.com

    Bristol-Myers Squibb: Balanced Segment Growth, The Pullback Is An Opportunity